# US 2018/0022797 A1 · Transthyretin antibodies and uses thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2018/0022797 A1 - Document ID: US20180022797A1 - Status: Published application - Kind: A1 - Application number: 15/716,154 - Filed: 2017-09-26 - Published: 2018-01-25 - Earliest claimed: 2013-02-08 - Assignees: Misfolding Diagnostics, Inc. - Applicants: Misfolding Diagnostics, Inc. - Inventors: Xin JIANG; Jeffery W. KELLY; Justin CHAPMAN - Web page: https://patentgrep.com/patent/US20180022797A1 ## CPC - C07K 16/18: against material from animals or humans - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps - A61P 25/00: Drugs for disorders of the nervous system - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - A61P 27/02: Ophthalmic agents - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention provides compositions comprising anti-transthyretin antibodies. The compositions are particularly useful for diagnosis, prognosis and/or treatment of amyloid diseases or symptoms thereof. ## Claims ### Claim 1 A method of administering an anti-aggregate agent to a subject in need thereof, comprising: a) administering said anti-aggregate agent to said subject at multiple time points; b) measuring a level of non-native TTR in said subject upon at least a first and second time point of said administration; c) adjusting dosage of said anti-aggregate agent and/or selecting a different anti-aggregate agent for administration based on said detected level of non-native TTR. ### Claim 2 (depends on 1) The method of claim 1, wherein said non-native TTR is measured by an assay utilizing an antibody that exhibits selective binding to non-native TTR under physiologically relevant conditions as compared to tetrameric TTR for said antibody binding. ### Claim 3 (depends on 1) The method of claim 1, wherein said anti-aggregate agent or therapy comprises a TTR kinetic stabilizer, wherein said TTR kinetic stabilizer stabilizes the TTR tetrameric form against dissociation. ### Claim 4 (depends on 1) The method of claim 1, wherein said anti-aggregate agent or therapy comprises an anti-TTR that reduces total TTR protein level. ### Claim 5 (depends on 1) The method of claim 1, wherein said first time point occurs before administering a first dosage of said anti-aggregate agent. ### Claim 6 (depends on 1) The method of claim 1, wherein said second time point occurs after administering a first dosage of said anti-aggregate agent. ### Claim 7 (depends on 1) The method of claim 1, comprising increasing dosage of said anti-aggregate agent if said detected level is increased by 20% or more at said second time point as compared to said first time point. ### Claim 8 A method of assessing the efficacy of an anti-aggregate therapy applied to a subject, comprising: measuring a change in the level of non-native TTR in said subject during said therapy, wherein said measuring is performed using an antibody that exhibits selective binding to non-native TTR under physiologically relevant conditions as compared to tetrameric TTR for said antibody binding, and wherein a decrease in the level of non-native TTR during said therapy indicates that said therapy is efficacious. ### Claim 9 (depends on 8) The method of claim 8, further comprising alerting said subject or caregiver thereof that said therapy is efficacious (1) if said change is a decrease in the level of non-native TTR, or (2) that said therapy is not efficacious if said change is not a decrease in the level of non-native TTR. ### Claim 10 (depends on 8) The method of claim 8, further comprising alerting said subject or caregiver thereof that said therapy is efficacious if said change is a decrease in the level of non-native TTR. ### Claim 11 (depends on 8) The method of claim 8, further comprising alerting said subject or caregiver thereof that said therapy is not efficacious if said change is not a decrease in the level of non-native TTR. ### Claim 12 (depends on 8) The method of claim 8, wherein said detection or measuring a level of non-native TTR comprises detecting or measuring in a biological sample obtained from said subject. ### Claim 13 (depends on 12) The method of claim 12, wherein said biological sample is a liquid sample. ### Claim 14 (depends on 8) The method of claim 8, wherein said subject is a human. ### Claim 15 (depends on 8) The method of claim 8, wherein said anti-aggregate agent or therapy comprises a TTR kinetic stabilizer, wherein said TTR kinetic stabilizer stabilizes the TTR tetrameric form against dissociation. ### Claim 16 (depends on 15) The method of claim 15, wherein said kinetic stabilizer is a benzoxazole. ### Claim 17 (depends on 16) The method of claim 16, wherein said benzoxazole is tafamidis. ### Claim 18 (depends on 16) The method of claim 16, wherein said kinetic stabilizer is diflunisal. ### Claim 19 (depends on 8) The method of claim 8, wherein said anti-aggregate agent or therapy comprises an anti-TTR that reduces total TTR protein level.